Reflux oesophagitis: a comparison of treatment with normal and slow release metoclopramide preparations

ABSTRACT

Twenty four patients with reflux oesophagitis were recruited into a crossover study of normal release metocloparmide [Maxolon tablets 10 mg three times a day] and slow release metocloparmide [Digestine capsules 40 mg equivalent to 16 mg metoclopramide HCI-once daily]. Both treatment regimens were found to be effective in the relief of reflux symptoms. The incidence of side effects was similar in both groups. Slow release was preferred by more patients. It is concluded that normal release metoclopramide given 10 mg three daily and slow release metoclopramide given 16 mg once daily are equally effective and both are well tolerated; however the slow release preparation has the advantage of smaller dose and once daily administration